Core Viewpoint - North China Pharmaceutical has received approval for two products: Vitamin B6 injection and injectable Isavuconazole, indicating a strategic expansion in both essential vitamins and high-end anti-infection markets [1][2][3] Group 1: Product Approvals - The company has been granted a supplementary approval for Vitamin B6 injection (1ml: 100mg) and a drug registration certificate for injectable Isavuconazole (0.2g) by the National Medical Products Administration [1][2] - Vitamin B6 is widely used in clinical settings for various metabolic disorders, with its indications expanding due to ongoing research [1] - The sales data from 2020 to 2023 shows fluctuations in Vitamin B6 injection sales, with a peak of 62.02 million yuan in 2021 and a decline to 46.37 million yuan in 2023 [1] Group 2: Market Strategy - The company plans to leverage its production and sales resources to expand sales channels and increase market coverage following the approval of the new Vitamin B6 injection specification [2] - North China Pharmaceutical aims to participate actively in national and provincial alliance procurement initiatives [2] - The company is considering further product pipeline development in the B vitamin sector based on market trends and strategic goals [2] Group 3: Financial and Competitive Position - The cumulative R&D investment for injectable Isavuconazole is reported to be 15.27 million yuan, and the product is expected to enhance the company's product line in the anti-infection sector [3] - The approval of Isavuconazole signifies the company's entry into the high-end anti-infection market, potentially providing new revenue growth opportunities [3] - The presence of five companies in the domestic market holding registration for injectable Isavuconazole indicates a competitive landscape, with the product achieving sales of 100 million yuan in 2023 [2][3]

汁性胆管炎患者而言，它可改善胆汁淤积状况，进而保护肝脏功能，延缓疾病的发展进程。在胆汁反流 性胃炎的治疗方面，熊去氧胆酸能够减轻胆汁对胃黏膜的损伤，极大地缓解患者的不适症状。 宝利化此次专利技术的突破，通过优化制备纯化装置与方法，极大地提升了熊去氧胆酸的纯度和质量稳 定性，为患者提供了更可靠、更有效的治疗选择和保障。在科研领域，高纯度的熊去氧胆酸样品是深入 研究其作用机制、探索新治疗用途的关键。该专利技术为科研工作提供了有力支持，有助于加速科研进 程，推动新型药物的研发。 值得一提的是，宝利化作为以科技创新与数字研发驱动的现代化制药集团，在专利研发方面成果丰硕。 此前，公司在维生素B6注射液研发领域就已成功获得专利，此次熊去氧胆酸相关专利的获得，是其创 新道路上的又一里程碑。这些专利成果充分体现了宝利化对研发创新的高度重视和持续投入，彰显了其 深厚的技术底蕴和强大的创新能力。 未来，宝利化将始终秉持"融合全球数药科技，守护人类生命健康"的使命，持续加大研发投入，深耕制 药创新领域，为患者带来更多安全、优质的产品和服务，为医疗健康事业发展贡献力量。 近日，宝利化（南京）制药有限公司在创新研发领域再传捷报，成功获 ...